Pharma brand and experience management is in the midst of a radical shift to take advantage of a rapidly digitizing healthcare ecosystem. Pharma brands have unique opportunity to become living asset for physicians, patients and employees. Those brands that embrace this opportunity will win, and will stand out for their relevance.

Top tips for building your ISO Quality Management System for Pharmaceutical Companies A Quality Management System (QMS) is key for pharma companies and should encourage organisations to comply with ICH Q10 and ISO guidance. Pharmaceutical QMS must also accommodate unique industry requirements to achieve core quality principles and other requirements by providing all the features […]

Pharma brand and experience management is in the midst of a radical shift to take advantage of a rapidly digitizing healthcare ecosystem. Pharma brands have unique opportunity to become living asset for physicians, patients and employees. Those brands that embrace this opportunity will win, and will stand out for their relevance.

Top tips for building your ISO Quality Management System for Pharmaceutical Companies A Quality Management System (QMS) is key for pharma companies and should encourage organisations to comply with ICH Q10 and ISO guidance. Pharmaceutical QMS must also accommodate unique industry requirements to achieve core quality principles and other requirements by providing all the features […]

Except for direct participation in clinical trials and post-approval activities such as disease education, patient involvement in the biopharmaceutical development process remains episodic and restricted. Although this is slowly changing, patient involvement at each step of a product lifecycle is not yet standard practice for most companies. WHY Engaging Patients is Key for Pharma’s Success […]

Connecting in the Digital Age How Pharmaceutical Companies Can Use Marketing Outreach to Better Engage with Global Consumers By Guillem Vidal, Welocalize Life Sciences, lifesciences.welocalize.com Most companies are stepping into the digital age when it comes to their marketing techniques and strategies, and pharmaceutical companies should be no different. For these companies to continue to […]

By Julien Moussalli Market Expansion Lead at IQVIA (LinkedIn: https://www.linkedin.com/in/julien-moussalli-80010349/) A makeover of the $65 billion clinical trials market (1) is well overdue. According to the National Cancer Institute, in the U.S only, 1.7 million people have been newly diagnosed with cancer in 2018 (2). In the meantime, pharma companies are trying to recruit thousands […]

Medical marijuana – or cannabis – is one of the hottest topics in oncology right now. This is especially true as more and more countries and states have legalized, or are working towards legalizing, medical cannabis. Some patient groups and alternative medicine providers view marijuana as a miracle treatment for a range of conditions. However, […]

Patient centricity, agility and digital capabilities are now the focus of many pharmaceutical companies to evolve one of the must important industries of our era. Just read some recent articles to confirm big-pharma is perusing evolution for a greater good ignited by these themes: MSD | Novartis | AZ | AbbVie | Sanofi | Among others We all can agree that entertainment, information […]

Pharma brand and experience management is in the midst of a radical shift to take advantage of a rapidly digitizing healthcare ecosystem. Pharma brands have unique opportunity to become living asset for physicians, patients and employees. Those brands that embrace this opportunity will win, and will stand out for their relevance.

Top tips for building your ISO Quality Management System for Pharmaceutical Companies A Quality Management System (QMS) is key for pharma companies and should encourage organisations to comply with ICH Q10 and ISO guidance. Pharmaceutical QMS must also accommodate unique industry requirements to achieve core quality principles and other requirements by providing all the features […]

Except for direct participation in clinical trials and post-approval activities such as disease education, patient involvement in the biopharmaceutical development process remains episodic and restricted. Although this is slowly changing, patient involvement at each step of a product lifecycle is not yet standard practice for most companies. WHY Engaging Patients is Key for Pharma’s Success […]

Connecting in the Digital Age How Pharmaceutical Companies Can Use Marketing Outreach to Better Engage with Global Consumers By Guillem Vidal, Welocalize Life Sciences, lifesciences.welocalize.com Most companies are stepping into the digital age when it comes to their marketing techniques and strategies, and pharmaceutical companies should be no different. For these companies to continue to […]

By Julien Moussalli Market Expansion Lead at IQVIA (LinkedIn: https://www.linkedin.com/in/julien-moussalli-80010349/) A makeover of the $65 billion clinical trials market (1) is well overdue. According to the National Cancer Institute, in the U.S only, 1.7 million people have been newly diagnosed with cancer in 2018 (2). In the meantime, pharma companies are trying to recruit thousands […]

Medical marijuana – or cannabis – is one of the hottest topics in oncology right now. This is especially true as more and more countries and states have legalized, or are working towards legalizing, medical cannabis. Some patient groups and alternative medicine providers view marijuana as a miracle treatment for a range of conditions. However, […]

Patient centricity, agility and digital capabilities are now the focus of many pharmaceutical companies to evolve one of the must important industries of our era. Just read some recent articles to confirm big-pharma is perusing evolution for a greater good ignited by these themes: MSD | Novartis | AZ | AbbVie | Sanofi | Among others We all can agree that entertainment, information […]

Pharma brand and experience management is in the midst of a radical shift to take advantage of a rapidly digitizing healthcare ecosystem. Pharma brands have unique opportunity to become living asset for physicians, patients and employees. Those brands that embrace this opportunity will win, and will stand out for their relevance.

Top tips for building your ISO Quality Management System for Pharmaceutical Companies A Quality Management System (QMS) is key for pharma companies and should encourage organisations to comply with ICH Q10 and ISO guidance. Pharmaceutical QMS must also accommodate unique industry requirements to achieve core quality principles and other requirements by providing all the features […]

Except for direct participation in clinical trials and post-approval activities such as disease education, patient involvement in the biopharmaceutical development process remains episodic and restricted. Although this is slowly changing, patient involvement at each step of a product lifecycle is not yet standard practice for most companies. WHY Engaging Patients is Key for Pharma’s Success […]

Connecting in the Digital Age How Pharmaceutical Companies Can Use Marketing Outreach to Better Engage with Global Consumers By Guillem Vidal, Welocalize Life Sciences, lifesciences.welocalize.com Most companies are stepping into the digital age when it comes to their marketing techniques and strategies, and pharmaceutical companies should be no different. For these companies to continue to […]

By Julien Moussalli Market Expansion Lead at IQVIA (LinkedIn: https://www.linkedin.com/in/julien-moussalli-80010349/) A makeover of the $65 billion clinical trials market (1) is well overdue. According to the National Cancer Institute, in the U.S only, 1.7 million people have been newly diagnosed with cancer in 2018 (2). In the meantime, pharma companies are trying to recruit thousands […]

Medical marijuana – or cannabis – is one of the hottest topics in oncology right now. This is especially true as more and more countries and states have legalized, or are working towards legalizing, medical cannabis. Some patient groups and alternative medicine providers view marijuana as a miracle treatment for a range of conditions. However, […]

Patient centricity, agility and digital capabilities are now the focus of many pharmaceutical companies to evolve one of the must important industries of our era. Just read some recent articles to confirm big-pharma is perusing evolution for a greater good ignited by these themes: MSD | Novartis | AZ | AbbVie | Sanofi | Among others We all can agree that entertainment, information […]

Pharma brand and experience management is in the midst of a radical shift to take advantage of a rapidly digitizing healthcare ecosystem. Pharma brands have unique opportunity to become living asset for physicians, patients and employees. Those brands that embrace this opportunity will win, and will stand out for their relevance.

Top tips for building your ISO Quality Management System for Pharmaceutical Companies A Quality Management System (QMS) is key for pharma companies and should encourage organisations to comply with ICH Q10 and ISO guidance. Pharmaceutical QMS must also accommodate unique industry requirements to achieve core quality principles and other requirements by providing all the features […]

Except for direct participation in clinical trials and post-approval activities such as disease education, patient involvement in the biopharmaceutical development process remains episodic and restricted. Although this is slowly changing, patient involvement at each step of a product lifecycle is not yet standard practice for most companies. WHY Engaging Patients is Key for Pharma’s Success […]

Connecting in the Digital Age How Pharmaceutical Companies Can Use Marketing Outreach to Better Engage with Global Consumers By Guillem Vidal, Welocalize Life Sciences, lifesciences.welocalize.com Most companies are stepping into the digital age when it comes to their marketing techniques and strategies, and pharmaceutical companies should be no different. For these companies to continue to […]

By Julien Moussalli Market Expansion Lead at IQVIA (LinkedIn: https://www.linkedin.com/in/julien-moussalli-80010349/) A makeover of the $65 billion clinical trials market (1) is well overdue. According to the National Cancer Institute, in the U.S only, 1.7 million people have been newly diagnosed with cancer in 2018 (2). In the meantime, pharma companies are trying to recruit thousands […]

Medical marijuana – or cannabis – is one of the hottest topics in oncology right now. This is especially true as more and more countries and states have legalized, or are working towards legalizing, medical cannabis. Some patient groups and alternative medicine providers view marijuana as a miracle treatment for a range of conditions. However, […]

Patient centricity, agility and digital capabilities are now the focus of many pharmaceutical companies to evolve one of the must important industries of our era. Just read some recent articles to confirm big-pharma is perusing evolution for a greater good ignited by these themes: MSD | Novartis | AZ | AbbVie | Sanofi | Among others We all can agree that entertainment, information […]

Pharma brand and experience management is in the midst of a radical shift to take advantage of a rapidly digitizing healthcare ecosystem. Pharma brands have unique opportunity to become living asset for physicians, patients and employees. Those brands that embrace this opportunity will win, and will stand out for their relevance.

Top tips for building your ISO Quality Management System for Pharmaceutical Companies A Quality Management System (QMS) is key for pharma companies and should encourage organisations to comply with ICH Q10 and ISO guidance. Pharmaceutical QMS must also accommodate unique industry requirements to achieve core quality principles and other requirements by providing all the features […]

Except for direct participation in clinical trials and post-approval activities such as disease education, patient involvement in the biopharmaceutical development process remains episodic and restricted. Although this is slowly changing, patient involvement at each step of a product lifecycle is not yet standard practice for most companies. WHY Engaging Patients is Key for Pharma’s Success […]

Connecting in the Digital Age How Pharmaceutical Companies Can Use Marketing Outreach to Better Engage with Global Consumers By Guillem Vidal, Welocalize Life Sciences, lifesciences.welocalize.com Most companies are stepping into the digital age when it comes to their marketing techniques and strategies, and pharmaceutical companies should be no different. For these companies to continue to […]

By Julien Moussalli Market Expansion Lead at IQVIA (LinkedIn: https://www.linkedin.com/in/julien-moussalli-80010349/) A makeover of the $65 billion clinical trials market (1) is well overdue. According to the National Cancer Institute, in the U.S only, 1.7 million people have been newly diagnosed with cancer in 2018 (2). In the meantime, pharma companies are trying to recruit thousands […]

Pharma brand and experience management is in the midst of a radical shift to take advantage of a rapidly digitizing healthcare ecosystem. Pharma brands have unique opportunity to become living asset for physicians, patients and employees. Those brands that embrace this opportunity will win, and will stand out for their relevance.

Top tips for building your ISO Quality Management System for Pharmaceutical Companies A Quality Management System (QMS) is key for pharma companies and should encourage organisations to comply with ICH Q10 and ISO guidance. Pharmaceutical QMS must also accommodate unique industry requirements to achieve core quality principles and other requirements by providing all the features […]

Except for direct participation in clinical trials and post-approval activities such as disease education, patient involvement in the biopharmaceutical development process remains episodic and restricted. Although this is slowly changing, patient involvement at each step of a product lifecycle is not yet standard practice for most companies. WHY Engaging Patients is Key for Pharma’s Success […]

Connecting in the Digital Age How Pharmaceutical Companies Can Use Marketing Outreach to Better Engage with Global Consumers By Guillem Vidal, Welocalize Life Sciences, lifesciences.welocalize.com Most companies are stepping into the digital age when it comes to their marketing techniques and strategies, and pharmaceutical companies should be no different. For these companies to continue to […]

By Julien Moussalli Market Expansion Lead at IQVIA (LinkedIn: https://www.linkedin.com/in/julien-moussalli-80010349/) A makeover of the $65 billion clinical trials market (1) is well overdue. According to the National Cancer Institute, in the U.S only, 1.7 million people have been newly diagnosed with cancer in 2018 (2). In the meantime, pharma companies are trying to recruit thousands […]

Medical marijuana – or cannabis – is one of the hottest topics in oncology right now. This is especially true as more and more countries and states have legalized, or are working towards legalizing, medical cannabis. Some patient groups and alternative medicine providers view marijuana as a miracle treatment for a range of conditions. However, […]

Patient centricity, agility and digital capabilities are now the focus of many pharmaceutical companies to evolve one of the must important industries of our era. Just read some recent articles to confirm big-pharma is perusing evolution for a greater good ignited by these themes: MSD | Novartis | AZ | AbbVie | Sanofi | Among others We all can agree that entertainment, information […]

As a result of rising healthcare costs, there have been widespread efforts to reform healthcare delivery worldwide. To succeed in this, many hospitals, health systems, and independent clinics are turning to clinical integration. Clinical Integration – What is it and Why Do We Need it? Overview of Clinical Integration. Source: Goldwater, J., Yuhasz, L. […]

by John Cahill Director/Snr Consultant, Quality and Compliance A disorderly Brexit is moving from a possibility to a probability. While governments pass last minute legislation over the month of March, it is encouraging to be part of a responsible industry that treats the threat to patients very seriously and has, according to our government officials, prepared very […]

A publisher friend recently suggested I write down what I knew about launching pharmaceutical brands, to help new marketers who may have been handed one of these opportunities for the first time. On the face of it, this challenge didn’t sound so difficult compared to some of the other advice I have shared openly. However, […]

With many patents about to expire in coming years, the field of biologics in oncology is about to change dramatically. Biologics are predicted to comprise over one-quarter of the pharmaceutical market by 2020. Currently, almost half of all biologics sales come from 11 major agents. All of these will have their patent expire in the […]

by Lorraine Lyons. Pharmaceutical Quality Consultant and Qualified Person (QP) with over 16 years’ experience in the Pharmaceutical Industry. Self-inspections support an organisation in accomplishing its objectives by bringing a systematic, disciplined approach to evaluating and improving the effectiveness of risk management, control and governance processes. Better self-inspection programmes should not only help ensure compliance and […]

What does it mean to be a drug rep / medical representative? What is this magical profession about, that forces all managers, executives and CEOs to stop for a while and direct efforts towards providing better opportunities for knowledge and professional skills increase of field force? The reason is that the drug reps are a […]

Just a decade ago, the job of a pharma sales rep was much desired among pharma professionals. DTC advertising did most of the heavy work, and sales reps only needed to finish the job. Physicians loved to see sales reps popping by and welcomed them in their offices. Then a major shift happened around 2011. […]

We have previously discussed the potential roles of real-world data (RWD) and real-world evidence (RWE) for drug access. However, the precise roles of RWE in facilitating regulatory and reimbursement decisions remain poorly defined. Specifically, the types of studies, quality of data, and level of evidence to consider in the reimbursement decision process remain largely unclear. […]

By Dr. Jonathan Trethowan, Vice President Regulatory and Scientific Policy at PharmaLex Every month, there are 45 million patient packs of medicines transported from the UK to the EU, and 37 million patient packs transported from the EU to the UK. These products are moved in complex supply chains, but in the case of a […]

Drugmakers Bristol-Myers Squibb and Celgene will pay about $1bn in fees to seal their $90bn tie-up, including more than $300m to their financial advisers, in one of the most lucrative advisory assignments ever recorded on Wall Street Source: https://www.ft.com/content/7dc80cda-27d9-11e9-88a4-c32129756dd8

Did you know that the top 10 highest grossing drugs in the United States only help between 4-25% of patients who take them? In addition, some drugs may even be harmful to certain minorities because of bias towards non-Hispanic white participants in traditional clinical trials. These statistics should be worrisome to physicians, patients, and payers. […]

What is Bionics and Why Should You Care? Bionics – also known as biomechatronics – is the study of mechanical systems that function like living organisms or parts thereof. More specifically, human bionics is an applied interdisciplinary science that integrates mechanical elements or devices with biological systems such as human bones, muscles, internal organs, and […]

Artificial intelligence, or AI for short, is one of the most highly anticipated digital healthcare technologies. While the concept of AI may still seem futuristic to some, the era of machine learning is already here. Uptake in pharma has been relatively slow compared to in other industries. However, this is gradually changing. AI is developing at […]

We have recently discussed several important considerations for pharma when looking into the future. While some future directions seem clear, such as the increased use of pharmacogenomics for personalized medicine, digital tools and neurotechnology apps, and incorporation of behavioral science in marketing and education efforts, others are more difficult to predict. In the setting of early and pre-launch pharmaceutical market research, one […]

Published on November 22, 2018 This week I had the honour of speaking at the UK Parliament about the value of gene editing in healthcare in the midst of Brexit negotiations and a controversial European Court ruling. Read on after the break for the full speech: From right to left: Ms Nunzia Florio (External Affairs Manager […]

It would be great to be one of those people who knew, from an early age, exactly what they wanted to be when they grew up. Neither a fighter pilot nor the “poster child” for a clearly mapped out career plan, I just passed twenty years of what was supposed to be a three-year working […]

After a tumultuous year of ups and downs, Teva Pharmaceuticals seems to be slowly turning the corner. The Israel based company saw a significant downturn in performance during 2017 attributed in part to shortsightedness of trends in the market, too rapid growth and leveraging, and most critically, failure to diversify its portfolio. Its focus on […]

As a globally minded business person, if you haven’t gained exposure to the numerous new laws and regulations emphasizing the rights of people to access, understand and be familiar with their personal data in the last six months, then you must have been living on another planet outside of our solar system. I am referring […]

“Turnaround, every now and then I get a little bit nervous That the best of all the years have gone by ……….” Remember this old song? Total Eclipse of the Heart, written by Jim Steinman and sung and recorded by Bonnie Tyler? Despite Bonnie’s heartfelt approach and having led a number of these in my career, […]

To stay relevant, pharma and healthcare companies need to move beyond the pill. Instead, the focus needs to shift to the broader patient journey. This includes changes in the way companies communicate with patients. One essential means of achieving this goal is the application of behavioral science to all aspects of drug development, marketing, and […]

Early screening, diagnosis, and management of cancer improve patient survival and reduce symptoms. However, while some common cancers such as breast, prostate, and cervical cancers are routinely screened for, many others are currently difficult to detect. Consequently, they are often detected in the late stages, adversely affecting the patients’ survival probability. In recent years, digital technologies […]

Digital Health: An Imperative Tool for Pharma The role of digital tools, such as mobile devices/apps, wearables, virtual assistants, and artificial intelligence (AI), in healthcare is quickly expanding. Pharmaceutical companies are increasingly integrating digital health into all services offered, including for treatment, follow-up, and prevention purposes. Additionally, they are shifting their focus from only providing drug-specific patient apps to developing more complex tools such as digital biomarkers to track various subjective or objective outcomes. As a result, digital health will likely play a major role in all aspects of healthcare in the future. However, for digital health to reach its full potential, there are still obstacles to overcome. In this article, we will explore some of the current and future uses of digital health and its benefits to both patients and pharma. Further, we will discuss the challenges to address before these tools can become widespread and the means to overcome these barriers. Digital Health Today Digital health tools serve multiple purposes. Basic health-related smartphone apps and wearables such as food diaries, exercise trackers, and heart rate monitors can help create awareness and improve general health. The ultimate hope is that these tools will minimize the risk of chronic lifestyle-related […]

Source: https://www.linkedin.com/pulse/evaluation-clinical-trial-costs-barriers-drug-luca-dezzani-md/ The complete analysis of the costs and barriers to drug development in 2018. All the expenses to conduct clinical trials and the split by disease areas Clinical trials are a crucial part of the drug development process. Pharmaceutical companies conduct clinical trials to demonstrate safety and efficacy in order to gain approval from regulatory bodies. In recent times, the cost of clinical trials has increased and the time it takes to bring a drug to market is becoming longer. In 2003, the estimated cost of bringing a drug to market was US$802 million. The cost is no longer the same. In 2016, The Tuft Center for the Study of Drug Development estimated the cost of the same process at $2.6 billion. The escalating cost of conducting clinical trials discourages pharmaceutical companies from traveling this path of drug development and consequently limits patients’ access to novel treatments. Many companies are looking for possible ways to cut down the cost of clinical trials and avoid barriers to drug development in order to improve drug development process. The cost of clinical trials varies amongst therapeutic areas and even from phase to phase. In phase 1 studies, Immunomodulation has the highest costs (US$6.6 million) and endocrine […]

Key Points FDA Commissioner Scott Gottlieb has initiated multiple policy actions to simplify the approval pathway for generic drug products Commissioner Gottlieb hopes these efforts will improve access to medications and lower healthcare costs The FDA has placed special focus on “complex” generic drug products, which have traditionally been difficult to “genericize” New policies are meant to reduce the number of review cycles and lower right-to-refuse rates for complex generic drug applications The FDA has defined complex drug products, created expedited approval pathways, offered opportunities for feedback/advice, and published numerous guidances to benefit complex generic drug development What Makes a Generic Drug Product “Complex”? In recent years, the FDA has taken steps to clarify the approval process for complex generic drug products. According to FDA Commissioner Scott Gottlieb, complex drug products “generally have at least one feature that makes them harder to ‘genericize’ under our traditional approaches.” These features can arise from formulation, characterization, or manufacturing considerations, as we’ve addressed in a previous post. When formulating a generic drug product, there are key sources of complexity that can be difficult to replicate: Active Ingredient: mixtures of APIs, polymeric compounds, peptides Formulation Technique: liposomes, suspensions, emulsions, gels Route of Delivery: locally-acting […]

Pharmacogenomics: A Brief Introduction Pharmacogenomics is the study of the role of the genome in drug responses. That is, it identifies genetic loci associated with known drug responses on a population-level. Some of the current pharmacogenomic approaches used include multigene analysis and whole-genome single nucleotide polymorphism profiles. Subsequently, the genetic variants affecting an individual’s drug […]

The Complete List and Analysis of the Best Pharmaceutical Companies for Cardiovascular in 2017 The global cardiovascular therapeutics market in 2017 was estimated at USD 129 billion and projected to grow at CAGR of 2.3% to reach USD 141.38 billion by 2021. The top 10 cardiovascular drugs accounted for revenue of USD 11.55 billion in […]

By Karin Bauer, VP Client Services, SGK Health Healthcare is an empathy-driven industry. But as healthcare consumers seek to become more empowered, changes in healthcare information gathering and sharing across systems have created a disconnect between the quantity of information available to empower care choices and the quality of care that patients receive. To win consumer confidence […]

Background As healthcare stakeholders begin to embrace real world evidence, along with many other forms of big data applications, there remains the issue of how to protect the underlying algorithms that derive meaning from this data. An algorithm is a very broad term that typically refers to the equations and/or a series of steps for […]

Besides the introduction we did, there was no unifying framework, so far we had seeing different models in an isolated way. Putting every framework in context is the purpose of this article. We believe that the best way to present this is by graphically depicting how the different models stack together in the following diagram: […]

Tactical war games are generally used for strengthening detailing in product launches and to develop successful counter-messages to competitors that are gaining share. Definitions and main hypothesis: A tactical war game is a simulation of a typical sales visit to get a thorough knowledge and understanding of the competition’s sales approach to develop own alternatives […]

What are “Real-world Data”? “Real-world data” (RWD) refer to data collected in a real-life setting within a heterogeneous population. That is, not in a randomized controlled trial (RCT). In turn, analysis of these multi-source data provides real-world evidence (RWE) supporting the value of a product. This is especially important to confirm its long-term safety and […]

Albert Einstein is widely credited with saying, “The definition of insanity is doing the same thing over and over again, but expecting different results.” While I do not view that choice as insane, I do see it as a common trap that most, if not all, in pharmaceutical sales seem to make. Here is how […]

LIFE SCIENCES FORCES OF CHANGE New and often asymmetrical competition is reshaping the market. Disruption is the new normal, the pace of innovation is accelerating, and data more important than ever. Furthermore, we have entered the era of the Millennial healthcare providers (HCPs) & patients with technology-dependent expectations and empowerment regarding care treatment, research and […]

By Neil Grubert, market access specialist, analyst and author. EU Study on Off-Label Prescribing In recent years, the pharmaceutical industry has been concerned by the precedent set by the off-label use on purely economic grounds of Roche/Genentech/Chugai’s Avastin (bevacizumab) as a replacement for Roche/Novartis’s Lucentis (ranibizumab) in the management of wet age-related macular degeneration (AMD). The […]

By Steve Figman The pace, scope, and variety of challenges we face as executives in Pharma are both invigorating and overwhelming. They span macro trends such as personalized medicine, real-world-evidence (RWE), onerous regulatory pressures, collaborative R&D and Digital health, as well as those specific to our businesses including post-merger integration, loss of exclusivity, market access […]

War games or competitive simulations, as some companies label them, are extremely useful in estimating, not only what the competitor will do, but also other players, such as the local FDAs, payors, physicians and other key players. Strategic war games are very flexible, as they are designed on an ad-hoc basis. But, let’s define what […]

The Complete List and Analysis of the Best Selling Oncology Drugs in 2017. All the Top Oncology Products in the Pharmaceutical and Biotechnology Industry with detailed performance and future trends Oncology remains the largest disease area in the pharmaceutical business followed by diabetology, rheumatology, anti-virals, and others. Total revenues for the 10 best selling oncology […]

Pharmaceutical companies live and die by their pipelines. Then, product launch excellence is key in the pharmaceutical business, as most of a new molecule’s success depends on the product launch. The current pharmaceutical market is tough and there are not many new products that can claim to be first-in-class or best-in-class. Additionally, many companies are […]

Before a new product launches, many manufacturers need to decide if they are going to initiate a Special Access Program (SAP; also referred to as an Early Access Program [EAP] in the US or a Compassionate Use Program [CUP] or Named Patient Program [NPP] in the EU) for their brand while they are going through […]

Sales and marketing functions within the pharmaceutical and biotech industries, at times, can resemble the social hierarchy at your old high school. Cliques posturing to be the cool kids on campus, each jockeying to lead, plan, and control the budget for the prom or class trip. While a healthy rivalry can be an effective driver […]

Pharmaceutical companies, in general, tend to neglect the role of competition in strategic analysis, in spite of being in markets where competition plays a significant role, as, usually, two or three players have 80%-90% combined market share per therapeutic category. To be fair, pharmaceutical companies are not alone in this, according to a McKinsey survey[1], […]

As David Bowie sang, Cha, Cha Changes. The pharmaceutical marketplace is no exception. While it was once easy for representatives to visit doctors, those days have long past. According to AccessMonitor, access to physicians has decreased from 80% in 2008 to 44% in 2016. That number will continue to decline. Then came direct to consumer […]

Five Debilitating Myths of Digital Pharma Marketing Pragmatic, informed digital marketing makes measurable gains in adoption and adherence. By Fred Geyer, Senior Partner at Prophet Digital pharma marketing is being preyed upon by myth-makers. Leading the pack are insurgent digital innovators who contribute digital savviness without appreciating the complexities of regulatory compliance and privacy protection. […]

The Complete List and Analysis of the Best Selling Drugs in 2017. All the Top Products in the Pharmaceutical and Biotechnology Industry with detailed performance and future trends In 2017, the global prescription drug market is estimated to be grown by 0.8% to reach USD 810 Billion and is further expected to grow at CAGR […]

Dear Colleagues, Stakeholders in healthcare have carried out research about the patient experience for a long time. Patient pathways are often examined in detail, and a number of good frameworks exist to help explain what that experience is like. Traditionally, though, most of that research was about the patient, not about the person with the disease. In his wise words “When a person is diagnosed with a long term chronic disease; that person finds another identity added to the mix, an identity they would very much like to abandon, or at the very least, forget”. I could not agree more with Kevin Dolgin, President at Observia. After her last pregnancy, my best friend developed hypertension. Dealing with that new situation has become a challenge for her and her family. She is an experienced healthcare professional and she understands the consequences of not following her doctor’s advice, however, many times she does not. And I wonder why. In his article “Understanding the person behind the patient: Using photo elicitation”, Kevin Dolgin discusses this problem, and explains how to use ethnographic research to begin to understand the decision making process of that complete person, with all of their different and complex identities You can read […]

SECURE BIG DATA WILL UNLEASH AGILE PHARMA BRAND MANAGEMENT A profound shift to rapid, iterative, data-driven brand management is about to take place in pharmaceuticals. It will significantly improve patient outcomes by enabling physicians and sufferers to obtain solutions that are better tailored to their needs without undermining the confidentiality of patient data that is so important to their trust. Pharma brands will transform from digital laggards to leaders by harnessing privacy protected data across the global healthcare ecosystem to improve sufferers’ paths to adoption and adherence. Conditions are ripe for a major shift: For the first time since the potential of digital healthcare emerged pharma leaders have the means and opportunity to effect agile brand management. The agility comes from newly available data sources that will enable brand leaders to adapt their go-to-market strategies rapidly and iteratively based on close to real time feedback. They will be able to target and tailor content more specifically, improve interactions and experiences more effectively and offer value-added services more broadly. Means: Pharma brands now have omni-channel access to sufferer and caregiver segments. They have it in their power to offer content, programs, services, access and formats at relevant steps in the path […]